A major infectious problem after organ transplantation, cytomegalovirus (CMV), could potentially be targeted with a vaccine, according to results from a phase II clinical trial led by scientists from UCL and doctors at the Royal Free Hospital.
The results of this proof-of-concept study show that a vaccine preparation moderated the severity of CMV infection in patients waiting for kidney and liver transplants and, in some cases, may have interrupted transmission of the virus from donor to recipient.
